

DT08 Rec'd PCT/PTO 03 MAR 2005


PATENT  
ATTORNEY DOCKET NO. 50304/056001

Certificate of Mailing: Date of Deposit: February 28, 2005

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**Guy Beardsley**

Printed name of person mailing correspondence

  
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	CARMELIET et al.	Art Unit:	To Be Assigned
Serial No.:	10/519,330	Examiner:	To Be Assigned
Filed:	December 23, 2004	Customer No.:	21559
Title:	PLACENTAL GROWTH FACTORS AS A TARGET FOR THE TREATMENT OF OSTEOPOROSIS		

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed, with the exception of U.S. patents and U.S. patent application publications. A copy of a search report from a corresponding international application is also enclosed.


Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

This statement is being filed before the receipt of a first Office action on the merits.

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: 28 February 2005

  
\_\_\_\_\_  
James D. DeCamp, Ph.D.  
Reg. No. 43,580

Clark & Elbing LLP  
101 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045



SUBSTITUTE FORM PTO-1449 (MODIFIED)  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No. 50304/056001  Serial No. 10/519,330  Applicant CARMELIET et al.  Filing Date December 23, 2004  Group  IDS Filed February 28, 2005		
U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Issue or Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
	6,369,204 B1	4/9/02	Kim et al.			
	2002/0009750	1/24/02	Rockwell et al.			
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	PCT/EP01/05478	11/15/01	WIPO			
	PCT/US02/19505	1/3/03	WIPO			
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
	Carmeliet et al., "Synergism Between Vascular Endothelial Growth Factor and Placental Growth Factor Contributes to Angiogenesis and Plasma Extravasation in Pathological Conditions", <i>Nature Medicine</i> , 7:575-583 (2001).					
	Mayr-Wohlfart et al., "Vascular Endothelial Growth Factor Stimulates Chemotactic Migration of Primary Human Osteoblasts", <i>Bone</i> , 30:472-477 (2002).					
	Niida et al., "Vascular Endothelial Growth Factor Can Substitute for Macrophage Colony-stimulating Factor in the Support of Osteoclastic Bone Resorption", <i>Journal of Experimental Medicine</i> , Vol. 190:293-298 (1999).					
EXAMINER			DATE CONSIDERED			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						